Insider Trading Alert - BSTC, TWO And CTRE Traded By Insiders

Yesterday, Nov. 16, 2015, 86 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,470.50 to $10,820,124.97.

Highlighted Stocks Traded by Insiders:

BioSpecifics Technologies (BSTC) - FREE Research Report

Wegman Thomas, who is President & CEO at BioSpecifics Technologies, sold 27,151 shares at $52.44 on Nov. 16, 2015. Following this transaction, the President & CEO owned 147,671 shares meaning that the stake was reduced by 15.53% with the 27,151-share transaction.

The shares most recently traded at $49.31, down $3.13, or 6.34% since the insider transaction. Historical insider transactions for BioSpecifics Technologies go as follows:

  • 4-Week # shares sold: 15,000
  • 12-Week # shares sold: 15,000
  • 24-Week # shares sold: 15,000

The average volume for BioSpecifics Technologies has been 82,700 shares per day over the past 30 days. BioSpecifics Technologies has a market cap of $359.7 million and is part of the health care sector and drugs industry. Shares are up 29.44% year-to-date as of the close of trading on Monday.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company has a P/E ratio of 42.3. Currently, there are no analysts who rate BioSpecifics Technologies a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BSTC - FREE

TheStreet Quant Ratings rates BioSpecifics Technologies as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full BioSpecifics Technologies Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Two Harbors Investment (TWO) - FREE Research Report

Roth William, who is Chief Investment Officer at Two Harbors Investment, bought 10,000 shares at $8.28 on Nov. 16, 2015. Following this transaction, the Chief Investment Officer owned 758,254 shares meaning that the stake was boosted by 1.34% with the 10,000-share transaction.

The shares most recently traded at $8.30, up $0.02, or 0.24% since the insider transaction. Historical insider transactions for Two Harbors Investment go as follows:

  • 4-Week # shares bought: 3,000
  • 4-Week # shares sold: 47,306
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 47,306
  • 24-Week # shares bought: 6,000
  • 24-Week # shares sold: 47,306

The average volume for Two Harbors Investment has been 2.9 million shares per day over the past 30 days. Two Harbors Investment has a market cap of $3.0 billion and is part of the financial sector and real estate industry. Shares are down 17.47% year-to-date as of the close of trading on Monday.

Two Harbors Investment Corp. The stock currently has a dividend yield of 12.55%. The company has a P/E ratio of 12.4. Currently, there are 9 analysts who rate Two Harbors Investment a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TWO - FREE

TheStreet Quant Ratings rates Two Harbors Investment as a hold. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself. Get the full Two Harbors Investment Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

CareTrust REIT (CTRE) - FREE Research Report

Sabin Gary B, who is Director at CareTrust REIT, bought 20,000 shares at $10.25 on Nov. 16, 2015. Following this transaction, the Director owned 32,160 shares meaning that the stake was boosted by 164.47% with the 20,000-share transaction.

The shares most recently traded at $10.46, up $0.21, or 2.01% since the insider transaction. Historical insider transactions for CareTrust REIT go as follows:

  • 4-Week # shares bought: 79,000
  • 12-Week # shares bought: 79,000
  • 24-Week # shares bought: 79,000

The average volume for CareTrust REIT has been 360,700 shares per day over the past 30 days. CareTrust REIT has a market cap of $499.8 million and is part of the financial sector and real estate industry. Shares are down 16.63% year-to-date as of the close of trading on Monday.

CareTrust REIT, Inc. (NasdaqGS:CTRE) operates independently of The Ensign Group, Inc. as of June 02, 2014. The stock currently has a dividend yield of 6.17%. The company has a P/E ratio of 61.1. Currently, there are 3 analysts who rate CareTrust REIT a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CTRE - FREE

TheStreet Quant Ratings rates CareTrust REIT as a sell. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself, unimpressive growth in net income and feeble growth in its earnings per share. Get the full CareTrust REIT Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Morgan Stanley M&A Prowess to Remain Strong; Google Dealt Another EU Fine--ICYMI

Morgan Stanley M&A Prowess to Remain Strong; Google Dealt Another EU Fine--ICYMI

Trump's Trade War Hurts U.S. Energy Companies, May Help China

Trump's Trade War Hurts U.S. Energy Companies, May Help China

One Chart Will Make You Even More Pumped Up to Buy Tech Stocks

One Chart Will Make You Even More Pumped Up to Buy Tech Stocks

Jim Cramer's Biggest Moments From Delivering Alpha

Jim Cramer's Biggest Moments From Delivering Alpha

'I Don't Think the Market Always Has the Right Idea' Says Bannon

'I Don't Think the Market Always Has the Right Idea' Says Bannon